GAP-AK
Research type
Research Study
Full title
Investigation of the genetic diversity, pathogenicity, and therapeutic targets in Acanthamoeba species isolated from patients with Acanthamoeba Keratitis
IRAS ID
353842
Contact name
Michael Leroy Kwame Ansah
Contact email
Sponsor organisation
Wellcome Sanger Institute
Duration of Study in the UK
2 years, 8 months, 31 days
Research summary
The aim of this investigation is to develop a better understanding of the genome of Acanthamoeba, a genus of microscopic single-celled organisms that are commonly found in water, soil and household dust. Acanthamoeba cause the eye infection Acanthamoeba keratitis (AK) in immunocompetent individuals. AK is characterised by inflammation and destruction of corneal tissue, resulting in damage to the cornea and in severe cases, irreversible sight loss. This study will look at the genome and the genetic factors that may contribute to pathogenicity, disease progression and poor treatment outcome in the disease Acanthamoeba keratitis. This will include investigating species/strains commonly found in clinical isolates and cultured strains, investigating any amoeba resistant organisms found with isolates, comparing the genomes of clinical isolates to similar species found in the environment or non-pathogenic Acanthamoeba species to identify genes associated with pathogenicity. Through whole-genome sequencing of both free-living and pathogenic Acanthamoeba strains, this research seeks to identify genes and proteins essential for the organism’s survival and pathogenicity, and their influence on keratitis severity, potentially highlighting new avenues for therapeutic targets. Additionally, we aim to explore Acanthamoeba’s interactions with other organisms within the corneal environment, investigating how these interactions might influence infection dynamics and outcomes.
REC name
London - Hampstead Research Ethics Committee
REC reference
25/PR/0460
Date of REC Opinion
29 Apr 2025
REC opinion
Further Information Favourable Opinion